一种杀粉蝶霉素类化合物及其在抗肿瘤药物制备中的应用

By isolating and purifying the cytotoxic compound Gricidin A from marine actinomycetes, the problems of poor efficacy and drug resistance in the treatment of non-small cell lung cancer by traditional therapies have been solved, and a significant inhibitory effect on non-small cell lung cancer cells has been achieved.

CN121930167BActive Publication Date: 2026-07-17SHANDONG INT BIOTECH PARK DEV +1
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANDONG INT BIOTECH PARK DEV
Filing Date
2026-03-30
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Traditional radiotherapy and chemotherapy have poor efficacy and significant side effects in treating non-small cell lung cancer, leading to tumor drug resistance and a lack of effective anti-tumor drugs.

Method used

Gricidin A, a cytotoxic compound, was isolated from the marine actinomycete Streptomyces sp. KCB-132 and purified using a specific process for application in the development of antitumor drugs.

Benefits of technology

Gricidin A exhibits significant inhibitory effects on non-small cell lung cancer cells, with IC50 values ​​ranging from 0.2 to 8.6 μM, demonstrating its potential for development into an anti-tumor drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121930167B_ABST
    Figure CN121930167B_ABST
Patent Text Reader

Abstract

本发明属于生物制药领域，公开了一种杀粉蝶霉素类化合物及其在抗肿瘤药物制备中的应用。所述的杀粉蝶霉素类化合物分离自海洋放线菌Streptomyces sp. KCB‑132的次生代谢产物，命名为Gricidin A。抗肿瘤活性实验发现，Gricidin A对3株非小细胞肺癌细胞（NCI‑H460、NCI‑H1975和A549）具有显著的抑制作用，具有开发成应对非小细胞肺癌药物的潜力。
Need to check novelty before this filing date? Find Prior Art